Xiaomin Wan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaomin Wan has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Meiyu Wu
19 shared publicationsShuxia Qin
Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
16 shared publicationsSini Li
16 shared publicationsChongqing Tan
14 shared publicationsLidan Yi
Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China
12 shared publicationsXiaohui Zeng
Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China
12 shared publications
Latest Publications
- 15 July 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (4) , e70221
Cost‐Effectiveness of Epcoritamab Plus Lenalidomide and Rituximab Versus Lenalidomide and Rituximab for Relapsed/Refractory Follicular Lymphoma: A US Payer Perspective
The Phase 3 EPCORE FL‐1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab ( R 2 ) significantly improved response rates and prolonged progression‐free survival in patients with relapsed or refractory ( r / r ) follicular lymphoma (FL). However, the cost‐effectiveness of this combination has not been evaluated. The objective of this study was to assess the cost‐effectiveness of epcoritamab plus R 2 compared with R 2 alone for patients with r / r FL from a US payer perspective. A three‐state Markov model was constructed with a 30‐year time horizon to compare costs and health outcomes of epcoritamab plus R 2 versus R 2 . The primary outcome was the incremental cost‐effectiveness ratio (ICER), expressed as cost per quality‐adjusted life‐year (QALY) gained. Parameter uncertainty was evaluated through one‐way sensitivity analysis, probabilistic sensitivity analysis, and scenario analyses. In the base‐case analysis, epcoritamab plus R 2 yielded an additional 3.94 QALYs at an incremental cost of $267,721.01 resulting in an ICER of $67,974.64 per QALY gained compared with R 2 alone. In the one‐way sensitivity analysis, the ICER ranged from $53,819.80 to $82,129.49 per QALY across all parameters tested. In the probabilistic sensitivity analysis, epcoritamab plus R 2 had a 100% probability of being cost‐effective at a willingness‐to‐pay (WTP) threshold of $150,000 per QALY. From a US payer perspective, epcoritamab plus R 2 is estimated to be a cost‐effective treatment option compared with R 2 for patients with relapsed or refractory follicular lymphoma at a willingness‐to‐pay threshold of $150,000 per QALY.
- 15 July 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (4) , e70221
Cost‐Effectiveness of Epcoritamab Plus Lenalidomide and Rituximab Versus Lenalidomide and Rituximab for Relapsed/Refractory Follicular Lymphoma: A US Payer Perspective
The Phase 3 EPCORE FL‐1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab ( R 2 ) significantly improved response rates and prolonged progression‐free survival in patients with relapsed or refractory ( r / r ) follicular lymphoma (FL). However, the cost‐effectiveness of this combination has not been evaluated. The objective of this study was to assess the cost‐effectiveness of epcoritamab plus R 2 compared with R 2 alone for patients with r / r FL from a US payer perspective. A three‐state Markov model was constructed with a 30‐year time horizon to compare costs and health outcomes of epcoritamab plus R 2 versus R 2 . The primary outcome was the incremental cost‐effectiveness ratio (ICER), expressed as cost per quality‐adjusted life‐year (QALY) gained. Parameter uncertainty was evaluated through one‐way sensitivity analysis, probabilistic sensitivity analysis, and scenario analyses. In the base‐case analysis, epcoritamab plus R 2 yielded an additional 3.94 QALYs at an incremental cost of $267,721.01 resulting in an ICER of $67,974.64 per QALY gained compared with R 2 alone. In the one‐way sensitivity analysis, the ICER ranged from $53,819.80 to $82,129.49 per QALY across all parameters tested. In the probabilistic sensitivity analysis, epcoritamab plus R 2 had a 100% probability of being cost‐effective at a willingness‐to‐pay (WTP) threshold of $150,000 per QALY. From a US payer perspective, epcoritamab plus R 2 is estimated to be a cost‐effective treatment option compared with R 2 for patients with relapsed or refractory follicular lymphoma at a willingness‐to‐pay threshold of $150,000 per QALY.
- Open Access
- 9 June 2026
- Published by Springer Nature in BMC Medicine
The economic burden of depression disease for China, India and the USA in 2025–2050: a health-augmented macroeconomic modelling study
Depression is an increasingly severe public health challenge worldwide, causing substantial health losses and profoundly impacting national economies. As China, India and the USA bear the largest share of the global depression burden and have different developmental and demographic profiles, quantifying the condition's long-term macroeconomic effects in these countries is crucial for gaining insight into the relationship between mental health and economic development worldwide. We used a health-augmented macroeconomic model to assess the macroeconomic impact of depression, comparing the difference in gross domestic product (GDP) between a status quo scenario and a counterfactual scenario in which depression was assumed to be completely eliminated between 2025 and 2050. The model incorporated human and physical capital channels, capturing productivity losses, reduced labour supply and declines in household savings caused by medical expenditures. Data were drawn from multiple publicly available sources, including literature, the Global Burden of Disease Study and the World Bank. From 2025 to 2050, the cumulative macroeconomic burden of depression is projected to reach INT $3,340 billion across the three countries. The USA is expected to bear the largest total and per capita losses, at INT $1,416 billion and INT $4,110 per person respectively. India would follow with INT $1,100 billion and INT $762 per person, while China would account for INT $873 billion and INT $615 per person. Across different economic models, depression has a significant and sustained negative impact on long-term macroeconomic development. Policymakers should take prompt action to implement effective prevention and management strategies to curb the growing health and economic impacts of depression.
- 9 June 2026
- Published by Springer Nature in BMC Medicine
Open AccessThe economic burden of depression disease for China, India and the USA in 2025–2050: a health-augmented macroeconomic modelling study
Depression is an increasingly severe public health challenge worldwide, causing substantial health losses and profoundly impacting national economies. As China, India and the USA bear the largest share of the global depression burden and have different developmental and demographic profiles, quantifying the condition's long-term macroeconomic effects in these countries is crucial for gaining insight into the relationship between mental health and economic development worldwide. We used a health-augmented macroeconomic model to assess the macroeconomic impact of depression, comparing the difference in gross domestic product (GDP) between a status quo scenario and a counterfactual scenario in which depression was assumed to be completely eliminated between 2025 and 2050. The model incorporated human and physical capital channels, capturing productivity losses, reduced labour supply and declines in household savings caused by medical expenditures. Data were drawn from multiple publicly available sources, including literature, the Global Burden of Disease Study and the World Bank. From 2025 to 2050, the cumulative macroeconomic burden of depression is projected to reach INT $3,340 billion across the three countries. The USA is expected to bear the largest total and per capita losses, at INT $1,416 billion and INT $4,110 per person respectively. India would follow with INT $1,100 billion and INT $762 per person, while China would account for INT $873 billion and INT $615 per person. Across different economic models, depression has a significant and sustained negative impact on long-term macroeconomic development. Policymakers should take prompt action to implement effective prevention and management strategies to curb the growing health and economic impacts of depression.
- 10 May 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (15) , 1919-1927
Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China
Metastatic urothelial carcinoma (mUC) is challenging to treat, with 37% of patients failing first-line therapy. Effective second-line treatments, like Erdafitinib, are crucial. This study evaluates the cost-effectiveness of Erdafitinib as a second-line treatment for mUC from US and Chinese payer perspectives. A Markov model was developed to project costs, life years, and quality-adjusted life years (QALYs) over lifetime. Data were collected from December 2023 to December 2024 for up-to-date estimates and were obtained from literature, health databases, and clinical trials.. The model was run to project long-term outcomes for both the United States and China. In the United States, Erdafitinib provides an additional 0.467 QALYs at a cost of $238,294.2 per QALY, which exceeds the $150,000 per QALY willingness-to-pay threshold. For China, when the cost of Erdafitinib is below $6.9 or $14 per milligram, there is a 90% probability that its incremental cost-effectiveness ratio will be below $38,223 or $84,966 per QALY, respectively. From the perspective of U.S. payers, Erdafitinib as a second-line treatment for mUC is not cost-effective. From the perspective of China, the cost-effectiveness of Erdafitinib is highly sensitive to its price, which could provide a reference for healthcare reimbursement negotiations.
- 10 May 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (15) , 1919-1927
Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China
Metastatic urothelial carcinoma (mUC) is challenging to treat, with 37% of patients failing first-line therapy. Effective second-line treatments, like Erdafitinib, are crucial. This study evaluates the cost-effectiveness of Erdafitinib as a second-line treatment for mUC from US and Chinese payer perspectives. A Markov model was developed to project costs, life years, and quality-adjusted life years (QALYs) over lifetime. Data were collected from December 2023 to December 2024 for up-to-date estimates and were obtained from literature, health databases, and clinical trials.. The model was run to project long-term outcomes for both the United States and China. In the United States, Erdafitinib provides an additional 0.467 QALYs at a cost of $238,294.2 per QALY, which exceeds the $150,000 per QALY willingness-to-pay threshold. For China, when the cost of Erdafitinib is below $6.9 or $14 per milligram, there is a 90% probability that its incremental cost-effectiveness ratio will be below $38,223 or $84,966 per QALY, respectively. From the perspective of U.S. payers, Erdafitinib as a second-line treatment for mUC is not cost-effective. From the perspective of China, the cost-effectiveness of Erdafitinib is highly sensitive to its price, which could provide a reference for healthcare reimbursement negotiations.
- Open Access
- 1 April 2025
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 31 (2) , 394-408
Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study
Background/Aims: The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination.Methods: Using an HCV transmission compartmental model, we evaluated the benefits and costs of different strategies combining screening and treatment for Chinese populations. We identified strategies to achieve HCV elimination and calculated the incremental cost-effectiveness ratios (ICERs) per disability-adjusted life year (DALY) averted for 2022–2030 to identify the optimal elimination strategy. Furthermore, we estimated the ROI by 2050 by comparing the required investment with the economic productivity gains from reduced HCV incidence and deaths.Results: The strategy that results in the most significant health benefits involves conducting annual primary screening at a rate of 14%, re-screening people who inject drugs annually and the general population every five years, and treating 95% of those diagnosed (P14-R4-T95), preventing approximately 5.75 and 0.44 million HCV infections and deaths, respectively, during 2022–2030. At a willingness-to-pay threshold of $12,615, the P14-R4-T95 strategy is the most cost-effective, with an ICER of $5,449/DALY. By 2050, this strategy would have a net benefit of $120,997 million (ROI=0.868).Conclusions: Achieving HCV elimination in China by 2030 will require significant investment in large-scale universal screening and treatment, but it will yield substantial health and economic benefits and is cost-effective.
- 1 April 2025
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 31 (2) , 394-408
Open AccessCost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study
Background/Aims: The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination.Methods: Using an HCV transmission compartmental model, we evaluated the benefits and costs of different strategies combining screening and treatment for Chinese populations. We identified strategies to achieve HCV elimination and calculated the incremental cost-effectiveness ratios (ICERs) per disability-adjusted life year (DALY) averted for 2022–2030 to identify the optimal elimination strategy. Furthermore, we estimated the ROI by 2050 by comparing the required investment with the economic productivity gains from reduced HCV incidence and deaths.Results: The strategy that results in the most significant health benefits involves conducting annual primary screening at a rate of 14%, re-screening people who inject drugs annually and the general population every five years, and treating 95% of those diagnosed (P14-R4-T95), preventing approximately 5.75 and 0.44 million HCV infections and deaths, respectively, during 2022–2030. At a willingness-to-pay threshold of $12,615, the P14-R4-T95 strategy is the most cost-effective, with an ICER of $5,449/DALY. By 2050, this strategy would have a net benefit of $120,997 million (ROI=0.868).Conclusions: Achieving HCV elimination in China by 2030 will require significant investment in large-scale universal screening and treatment, but it will yield substantial health and economic benefits and is cost-effective.
- 21 February 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (4) , 1597-1606
Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysis
Objective Compared with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologics are more effective and are recommended to be included in the sequential treatment for psoriatic arthritis (PsA) patients. However, biologics are expensive and the cost-effectiveness of sequential biologic therapy in China remains unknown. The purpose of this study is to evaluate the cost-effectiveness of different sequential treatment option for PsA patients who have not responded to csDMARDs from the perspective of Chinese healthcare system. Methods We constructed a discrete event simulation model to evaluate the cost-effectiveness of 7 monotherapy treatments and 32 sequential treatments. In sequential therapy, two different types of biologics were used as first-line and second-line treatments, respectively, with the best supportive care (BSC) as the third-line treatment. The primary outcomes included total treatment costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way and probability sensitivity analyses were performed to explore the uncertainty of our model. Results Compared to all other strategies, initiating with secukinumab followed by etanercept (SEC-ETN) provided the highest health benefits. At a willingness-to-pay (WTP) threshold of US $38,161 per QALY, SEC-ETN was the most cost-effective strategy, with an ICER of $20,837 per QALY. One-way sensitivity analysis and probabilistic sensitivity analysis results confirmed the robust of this conclusion. Conclusions In China, SEC-ETN may be the most cost-effective strategy for patients who have failed treatment with csDMARDs and have not previously used biologics. The results provide evidence for identifying the optimal biologic treatment strategy for PsA patients in China. Key Points • Compared with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologics are more effective and are recommended to be included in the sequential treatment for psoriatic arthritis (PsA) patients. However, the cost-effectiveness of sequential biologic therapy in China remains unclear. • At a willingness-to-pay threshold of $38,161, initiating with secukinumab followed by etanercept (SEC-ETN) was cost-effective strategy, outperforming other strategies. • From the perspective of the Chinese healthcare system, the optimal biologic treatment strategy was SEC-ETN in China.
- 21 February 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (4) , 1597-1606
Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysis
Objective Compared with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologics are more effective and are recommended to be included in the sequential treatment for psoriatic arthritis (PsA) patients. However, biologics are expensive and the cost-effectiveness of sequential biologic therapy in China remains unknown. The purpose of this study is to evaluate the cost-effectiveness of different sequential treatment option for PsA patients who have not responded to csDMARDs from the perspective of Chinese healthcare system. Methods We constructed a discrete event simulation model to evaluate the cost-effectiveness of 7 monotherapy treatments and 32 sequential treatments. In sequential therapy, two different types of biologics were used as first-line and second-line treatments, respectively, with the best supportive care (BSC) as the third-line treatment. The primary outcomes included total treatment costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way and probability sensitivity analyses were performed to explore the uncertainty of our model. Results Compared to all other strategies, initiating with secukinumab followed by etanercept (SEC-ETN) provided the highest health benefits. At a willingness-to-pay (WTP) threshold of US $38,161 per QALY, SEC-ETN was the most cost-effective strategy, with an ICER of $20,837 per QALY. One-way sensitivity analysis and probabilistic sensitivity analysis results confirmed the robust of this conclusion. Conclusions In China, SEC-ETN may be the most cost-effective strategy for patients who have failed treatment with csDMARDs and have not previously used biologics. The results provide evidence for identifying the optimal biologic treatment strategy for PsA patients in China. Key Points • Compared with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologics are more effective and are recommended to be included in the sequential treatment for psoriatic arthritis (PsA) patients. However, the cost-effectiveness of sequential biologic therapy in China remains unclear. • At a willingness-to-pay threshold of $38,161, initiating with secukinumab followed by etanercept (SEC-ETN) was cost-effective strategy, outperforming other strategies. • From the perspective of the Chinese healthcare system, the optimal biologic treatment strategy was SEC-ETN in China.
- 9 January 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (4) , 577-585
Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis
Biologics are recommended for use in patients with psoriatic arthritis (PsA) after the failure of conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs). However, compared to csDMARDs, biologics are significantly more expensive. The aim of this study was to evaluate the cost-effectiveness of biologic treatments for active PsA patients who have failed treatment with csDMARDs, from the perspective of the Chinese healthcare system. A discrete event simulation model was constructed to estimate health and economic outcomes of patients. The seven biologics recommended by the Chinese psoriasis treatment guidelines were included in the evaluation. One-way and probabilistic sensitivity analysis were performed to ensure that our results were robust. Our results found that compared to the standard of care (SoC) and all other biologics strategies, secukinumab (SEC) had the highest quality-adjusted life years, and at a willingness-to-pay (WTP) threshold of US $38,161 per QALY, SEC was the most cost-effective option, with an incremental cost-effectiveness ratio of $14,968 per QALY. One-way sensitivity analysis and probabilistic sensitivity analysis confirmed the robust of this result. From the perspective of the Chinese healthcare system, biologics are estimated to be cost-effective compared to SoC. Among these, SEC is the most cost-effective option.
- 9 January 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (4) , 577-585
Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis
Biologics are recommended for use in patients with psoriatic arthritis (PsA) after the failure of conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs). However, compared to csDMARDs, biologics are significantly more expensive. The aim of this study was to evaluate the cost-effectiveness of biologic treatments for active PsA patients who have failed treatment with csDMARDs, from the perspective of the Chinese healthcare system. A discrete event simulation model was constructed to estimate health and economic outcomes of patients. The seven biologics recommended by the Chinese psoriasis treatment guidelines were included in the evaluation. One-way and probabilistic sensitivity analysis were performed to ensure that our results were robust. Our results found that compared to the standard of care (SoC) and all other biologics strategies, secukinumab (SEC) had the highest quality-adjusted life years, and at a willingness-to-pay (WTP) threshold of US $38,161 per QALY, SEC was the most cost-effective option, with an incremental cost-effectiveness ratio of $14,968 per QALY. One-way sensitivity analysis and probabilistic sensitivity analysis confirmed the robust of this result. From the perspective of the Chinese healthcare system, biologics are estimated to be cost-effective compared to SoC. Among these, SEC is the most cost-effective option.
- Open Access
- 5 November 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1382342
Evaluating nivolumab plus gemcitabine–cisplatin’s cost-effectiveness for aUC in China
Aims: Assessing the cost-effectiveness of Nivolumab with Gemcitabine–Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.Methods: A Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainties on the results.Results: The base-case analysis showed Nivolumab plus Gemcitabine–Cisplatin yielded 0.59 QALYs at an extra cost of $78,780.61, leading to an incremental cost-effectiveness ratios (ICER) of $133,526.46/QALY. One-way sensitivity analysis highlighted Nivolumab’s cost as the key factor, while probabilistic sensitivity analysis showed a 0% chance of cost-effectiveness for Nivolumab plus Gemcitabine–Cisplatin in aUC treatment.Conclusion: Nivolumab plus Gemcitabine–Cisplatin is not cost-effective in the treatment of aUC.
- 5 November 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1382342
Open AccessEvaluating nivolumab plus gemcitabine–cisplatin’s cost-effectiveness for aUC in China
Aims: Assessing the cost-effectiveness of Nivolumab with Gemcitabine–Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.Methods: A Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainties on the results.Results: The base-case analysis showed Nivolumab plus Gemcitabine–Cisplatin yielded 0.59 QALYs at an extra cost of $78,780.61, leading to an incremental cost-effectiveness ratios (ICER) of $133,526.46/QALY. One-way sensitivity analysis highlighted Nivolumab’s cost as the key factor, while probabilistic sensitivity analysis showed a 0% chance of cost-effectiveness for Nivolumab plus Gemcitabine–Cisplatin in aUC treatment.Conclusion: Nivolumab plus Gemcitabine–Cisplatin is not cost-effective in the treatment of aUC.
- Open Access
- 9 September 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1464092
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
Background and objective: The EV-302 trial found that the combination of enfortumab vedotin (EV) with pembrolizumab significantly improved survival for patients with metastatic urothelial carcinoma (mUC). However, given the high cost of the drugs, there is a need to assess its value by considering both efficacy and cost. This study assessed the cost-effectiveness of EV plus pembrolizumab as a first-line treatment for patients with mUC from the perspective of U.S. payers.Methods: A Markov model was developed to compare the lifetime costs and effectiveness of EV in combination with pembrolizumab with chemotherapy in the treatment of mUC patients from U.S. payer perspective. Life-years (LYs), quality-adjusted LYs (QALYs), and lifetime costs were estimated. One-way, two-way and probabilistic sensitivity analyses were conducted to evaluate model uncertainty. Additionally, subgroup analyses were performed.Results: Compared to chemotherapy, the combination of EV and pembrolizumab provided an additional 2.10 LYs and 1.72 QALYs, at an incremental cost of $962,240.8 per patient. The incremental cost-effectiveness ratio (ICER) is $558,973 per QALY. Subgroup analysis indicated that patients ineligible for cisplatin treatment had a lower ICER compared to those who were eligible for cisplatin.Conclusions: From the perspective of US payers, at a willingness-to-pay threshold of $150,000 per QALY, the combination of EV and pembrolizumab is estimated to not be cost-effective compared to traditional chemotherapy in the first-line treatment of mUC patients.
- 9 September 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1464092
Open AccessCost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
Background and objective: The EV-302 trial found that the combination of enfortumab vedotin (EV) with pembrolizumab significantly improved survival for patients with metastatic urothelial carcinoma (mUC). However, given the high cost of the drugs, there is a need to assess its value by considering both efficacy and cost. This study assessed the cost-effectiveness of EV plus pembrolizumab as a first-line treatment for patients with mUC from the perspective of U.S. payers.Methods: A Markov model was developed to compare the lifetime costs and effectiveness of EV in combination with pembrolizumab with chemotherapy in the treatment of mUC patients from U.S. payer perspective. Life-years (LYs), quality-adjusted LYs (QALYs), and lifetime costs were estimated. One-way, two-way and probabilistic sensitivity analyses were conducted to evaluate model uncertainty. Additionally, subgroup analyses were performed.Results: Compared to chemotherapy, the combination of EV and pembrolizumab provided an additional 2.10 LYs and 1.72 QALYs, at an incremental cost of $962,240.8 per patient. The incremental cost-effectiveness ratio (ICER) is $558,973 per QALY. Subgroup analysis indicated that patients ineligible for cisplatin treatment had a lower ICER compared to those who were eligible for cisplatin.Conclusions: From the perspective of US payers, at a willingness-to-pay threshold of $150,000 per QALY, the combination of EV and pembrolizumab is estimated to not be cost-effective compared to traditional chemotherapy in the first-line treatment of mUC patients.